Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
about
Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancerAngiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectivesIdentification of novel drug targets for the treatment of diabetic retinopathy.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkersRegulation of endothelial Fas expression as a mechanism of promotion of vascular integrity by mural cells in tumors.Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcomaIntratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer.Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2.Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphomaInsulin-resistant subjects have normal angiogenic response to aerobic exercise training in skeletal muscle, but not in adipose tissue.Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activitiesTumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.MULTIMERIN2 binds VEGF-A primarily via the carbohydrate chains exerting an angiostatic function and impairing tumor growth.Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumabElevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding.Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?Tumor vasculature: the Achilles' heel of cancer?Molecular insights for optimizing T cell receptor specificity against cancer.Understanding and targeting resistance to anti-angiogenic therapies.The dynamics of developmental and tumor angiogenesis-a comparison.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers.Gln-362 of angiopoietin-2 mediates migration of tumor and endothelial cells through association with α5β1 integrin.Prognostic significance of TIE2-expressing monocytes in hilar cholangiocarcinoma.Neovascularization in Glioblastoma: Current Pitfall in Anti-angiogenic therapy.Tumor necrosis factor-α levels and non-surgical bleeding in continuous-flow left ventricular assist devices.Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis.Expression and localization of angiopoietin family in corpus luteum during different stages of oestrous cycle and modulatory role of angiopoietins on steroidogenesis, angiogenesis and survivability of cultured buffalo luteal cells.Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer.Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain.Molecular Ablation of Tumor Blood Vessels Inhibits Therapeutic Effects of Radiation and Bevacizumab.
P2860
Q26991997-BE20D8B6-9A44-42B5-823D-C0151A4715B2Q27006707-8E7C18C7-6988-4A05-814B-5F50430ACC54Q31134280-4FD6F7FE-6EF1-40E7-9375-C802C4378E2DQ33410375-37B8D56C-D585-44FB-BCA0-E453EADA2B69Q33415397-93980BD6-02C1-4A3A-BE88-AA6DC573BF95Q33738744-26A5A6BA-7F9A-4DD8-9DF2-54D10513D975Q33823827-37E9B83F-10FB-4DC1-82E5-825849B13B53Q33919862-2AE753AD-1A9A-4D33-9A5F-0456E9DBBEA0Q34937019-05742F55-17C7-4D3E-9DF0-EF70B684DF76Q35640953-5E6E1D81-0BFE-4F8D-808E-33E624B05971Q35695381-6CA05778-8A0F-4F78-8CE3-B72E4D6C546FQ35719490-75832A45-1993-4034-8722-0778AC055E2FQ35797583-3ECB3558-79D6-441F-835F-9A88F6A330FEQ35877539-01BC943C-F84F-4ABD-AF3E-184902193CB2Q36223964-D16E06B6-3E8C-4C24-B3B1-06D00710E826Q36336679-D6B353C3-E98D-41BC-A692-F017DBB3EE26Q36428702-1B99D3AB-9F7C-4AA2-A7D4-801AA3835465Q36739030-818DE4B1-AEC1-4583-809D-76B8B22E35BEQ36804893-5C4E15DE-C8B8-45FB-B7DA-3C7BC7C6ED06Q37088633-0CC62679-9E8D-4E4E-9444-470C81EDFC7FQ37236229-199BBA75-C23B-4D3F-95B3-031C64C953EEQ38057420-ED66A7F0-EBEC-4624-B763-D4EEA13C808AQ38117139-DD619325-505F-48F6-93A2-D3CC08A59CA0Q38133568-FBFC5ACA-2996-4D28-98F8-56DDC2BF47D7Q38161389-4287F054-0E16-44CC-BA49-E95270CD15C5Q38498207-96174217-37E5-4ED0-BBA2-5447D19A71B2Q38763633-AA690B11-5771-4F2D-9D25-A8A61464EA49Q38943409-A6E34E21-4F48-4944-9956-EC3633885AA6Q38955120-D1744691-7792-43C9-8B44-397712B888FCQ39824985-7B780B31-DD02-4613-A522-227D18DB3199Q41383985-9C93833F-3100-4643-875C-66F1710328ADQ47124541-C25D7348-D9E3-4EB7-A391-8846703215F4Q47401268-DE144B1D-A871-4E16-8D85-BA30D994102EQ47860210-B9105441-C5A9-4D5C-B5DF-56BFEAC94C68Q49544357-C1AF1425-405F-4D83-9B45-66518A30CA36Q50968798-56AE8719-CFB8-4B03-A5A4-B72D3DE52CF1Q52646854-113D614D-CBAC-4A5B-B95A-5901AB91BA11Q55457297-46D5DA7A-232A-4FA4-A370-3162869D18D8
P2860
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
@en
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
@nl
type
label
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
@en
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
@nl
prefLabel
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
@en
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
@nl
P356
P1476
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
@en
P2093
Tina Cascone
P304
P356
10.1200/JCO.2011.38.7621
P407
P577
2011-12-19T00:00:00Z